Oncology Pharma Inc (ONPH) Stock Price, Trades & News

	Name	Value
	Revenue (TTM) (Mil $)	0.094
	EPS (TTM) ($)	-
	Beta	-129.0886
	3-Year Sharpe Ratio	0.95
	3-Year Sortino Ratio	14.75
	Volatility %	3323.06
	14-Day RSI	45.26
	14-Day ATR ($)	0.022452
	20-Day SMA ($)	0.062658
	12-1 Month Momentum %	61900
	52-Week Range ($)	0.0001 - 0.364
	Shares Outstanding (Mil)	37.96

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Oncology Pharma Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Oncology Pharma Inc Stock Events

Financials Calendars

Event	Date	Price ($)
0.01:1 Stock Split	2020-10-09	0.78 (+27.87%)
0.0001:1 Stock Split	2016-01-04	100.00 (-50.00%)
0.002:1 Stock Split	2013-07-08	200,000.00 (-50.00%)
0.25:1 Stock Split	1999-08-26	4,436,000,000.00 (+0.00%)

Show

Entries

Oncology Pharma Inc Frequently Asked Questions

What is Oncology Pharma Inc(ONPH)'s stock price today?

The current price of ONPH is $0.05. The 52 week high of ONPH is $0.36 and 52 week low is $0.00.

When is next earnings date of Oncology Pharma Inc(ONPH)?

The next earnings date of Oncology Pharma Inc(ONPH) is .

Does Oncology Pharma Inc(ONPH) pay dividends? If so, how much?

Oncology Pharma Inc(ONPH) does not pay dividend.

Guru Commentaries on OTCPK:ONPH

No articles.

Press Release

	Subject	Date
	Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	2022-07-12
	Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	2022-06-29
	Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development	2022-06-08
	Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development	2022-05-09
	Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer	2022-04-13
	Oncology Pharma Reports on Progress with Ribera Solutions	2022-03-02
	Oncology Pharma Releases Further Feasibility Studies, Data and Capacities	2022-02-23
	Oncology Pharma Expands on Feasibility Studies and Data	2022-02-17
	Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine	2022-02-14
	Oncology Pharma Gives Update on Technology, Formulation and Data Creation	2022-02-08

10/Page

Articles on Oncology Pharma Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.